Comparing Two Second-Line Regimens for Non-Hodgkin Lymphoma

Outcomes were similarly poor among patients with aggressive disease.

The standard treatment for patients with diffuse large B-cell lymphoma (DLBCL) who experience disease progression after initial therapy is second-line chemotherapy followed by high-dose therapy (HDT) and hematopoietic stem-cell transplantation (SCT).

To compare the efficacy of two such second-line regimens, investigators conducted a multinational, phase III trial involving 396 patients (age range, 18–65) with aggressive B-cell non-Hodgkin lymphoma (383 with DLBCL). All patients had failed to achieve complete remission or had experienced relapse after initial therapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a CHOP-like regimen, with or without rituximab. Patients were randomized to receive R-DHAP (rituximab pl…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee